<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03784040</url>
  </required_header>
  <id_info>
    <org_study_id>GA01/03/18</org_study_id>
    <secondary_id>2018/00422</secondary_id>
    <nct_id>NCT03784040</nct_id>
  </id_info>
  <brief_title>Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.</brief_title>
  <acronym>da VINci</acronym>
  <official_title>da VINci Study (OTSGC-A24 Therapeutic Peptide Vaccine + Ipilimumab + Nivolumab) Nivolumab, Ipilimumab and OTSGC-A24 Therapeutic Peptide Vaccine in Gastric Cancer - a Combination Immunotherapy Phase Ib Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>OncoTherapy Science, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary hypothesis is that cancer vaccine can convert non-immunogenic gastric cancer into&#xD;
      immunogenic phenotype susceptible to PD1 inhibition. This would lead to an improved&#xD;
      radiological response rate and favorable immune contexture for immune checkpoint blockade&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Objectives&#xD;
&#xD;
        1. Safety cohorts: To evaluate the safety of OTSGC-A24 and nivolumab (+ ipilimumab) in&#xD;
           patients with refractory gastric cancer.&#xD;
&#xD;
        2. Arm A: To determine the objective response rate of OTSGC-A24 and nivolumab in advanced&#xD;
           gastric cancer.&#xD;
&#xD;
        3. Arm B: To determine the objective response rate of OTSGC-A24 and nivolumab + ipilimumab&#xD;
           in advanced gastric cancer.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        1. To compare the difference in objective response rates between Arm A and Arm B&#xD;
&#xD;
        2. To compare the tumoral immune contexture and PDL-1 expression before treatment, after&#xD;
           OTSGC-A24, and after nivolumab (+ ipilimumab) in combination with OTSGC-A24.&#xD;
&#xD;
        3. To determine the serum cytotoxic T-cell response using enzyme-linked immunospot assay&#xD;
           (ELISPOT) in PBMC.&#xD;
&#xD;
        4. To determine the progression-free survival (PFS) and overall survival (OS) of Arm A and&#xD;
           Arm B.&#xD;
&#xD;
        5. To evaluate the effect of OTSGC-A24 and nivolumab + ipilimumab on clinical and immune PD&#xD;
           markers.&#xD;
&#xD;
        6. Evaluate the effects of treatment on peripheral T-cell phenotypic profiles with&#xD;
           epitope-specificities by coupling mass cytometric analyses with highly-multiplexed&#xD;
           peptide-MHC tetramer staining technology.&#xD;
&#xD;
        7. Identify potential biomarkers for treatment response and mechanisms of secondary&#xD;
           resistance by studying gene expression profiles and phenotypic/functional markers of&#xD;
           tumour and infiltrating immune cells.&#xD;
&#xD;
      End Points - Efficacy&#xD;
&#xD;
      The endpoints for efficacy are:&#xD;
&#xD;
        -  Induction of specific CTL response after vaccination&#xD;
&#xD;
        -  Response rate&#xD;
&#xD;
        -  Progression-free survival&#xD;
&#xD;
        -  Overall survival End Points - Safety&#xD;
&#xD;
      The endpoints for safety are:&#xD;
&#xD;
      • overall adverse events observed, treatment-related adverse events, and category (eg&#xD;
      percentage of patients with any-grade treatment-related adverse events and grade 3-4&#xD;
      treatment-related adverse events).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 21, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Event and Adverse Drug Reaction</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response Rate</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of induction of specific CTL response</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>(Arm A) OTSGC-A24 + nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14 each 28 day cycle (q28d) for up to 24 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Arm B) OTSGC-A24 + nivolumab + ipilimumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study subjects will receive nivolumab 240 mg intravenously (IV) and OTSGC-A24 consisted of 1 μmol (~1 mg) of OTSGC-A24-Fo, OTSGC-A24-De, OTSGC-A24-Ki, OTSGC-A24-VE1 and OTSGC-A24-Ur 1.0 μmol (as API) administered subcutaneously on Day 1 and D14. Ipilimumab 1mg/kg (IV) will be administered q6w (i.e. C1D1, C2D15, C3D1 …) of each 28 day cycle for up to 24 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OTSGC-A24</intervention_name>
    <description>OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.</description>
    <arm_group_label>(Arm A) OTSGC-A24 + nivolumab</arm_group_label>
    <arm_group_label>(Arm B) OTSGC-A24 + nivolumab + ipilimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.</description>
    <arm_group_label>(Arm A) OTSGC-A24 + nivolumab</arm_group_label>
    <arm_group_label>(Arm B) OTSGC-A24 + nivolumab + ipilimumab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>OTSGC-A24 is administered as a subcutaneous (under the skin) injection. Nivolumab and ipilimumab are administered by intravenous (IV) infusion, meaning the drug is given through a catheter in a vein. A pump will be used to ensure the correct amount of medicine is given through the catheter. The nivolumab and ipilimumab infusions each take about 30 minutes. There will be a break of about 30 minutes in between the nivolumab and ipilimumab infusions (if given on the same day). OTSGC-A24 and nivolumab are administered every 2 weeks, while ipilimumab is administered every 6 weeks.</description>
    <arm_group_label>(Arm B) OTSGC-A24 + nivolumab + ipilimumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Histologically or cytologically confirmed inoperable or metastatic gastric cancer that&#xD;
             has failed or demonstrated intolerance to standard therapy - which includes platinum&#xD;
             or fluoropyrimidine or taxane based chemotherapy.&#xD;
&#xD;
          2. Patients must have measurable disease.&#xD;
&#xD;
          3. Age ≥ 21 years&#xD;
&#xD;
          4. ECOG performance status (PS) of 0 to 1&#xD;
&#xD;
          5. Life expectancy at least 3 months&#xD;
&#xD;
          6. Patients must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥ 1,500/mcL&#xD;
&#xD;
               -  Platelets ≥ 100,000/mcL&#xD;
&#xD;
               -  Total bilirubin within normal institutional limits&#xD;
&#xD;
               -  AST(SGOT)/ALT(SGPT) ≤ 2.5 X institutional upper limit of normal&#xD;
&#xD;
               -  Creatinine &lt;1.5x normal institutional limits&#xD;
&#xD;
          7. Patients must be HLA-A*24:02&#xD;
&#xD;
          8. Patients must have recovered (&lt; grade 1) from all reversible treatment toxicity from&#xD;
             prior chemotherapy, radiotherapy or surgery.&#xD;
&#xD;
          9. Ability to understand and the willingness to sign a written informed consent document.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients receiving any other investigational products&#xD;
&#xD;
          2. Patients who have previously received prior nivolumab or PD-/L1 blockade therapy&#xD;
&#xD;
          3. Active autoimmune disease requiring disease-modifying therapy.&#xD;
&#xD;
          4. Concurrent systemic steroid therapy higher than physiologic dose (equivalent of&#xD;
             prednisolone 10mg daily)&#xD;
&#xD;
          5. Any form of active primary or secondary immunodeficiency.&#xD;
&#xD;
          6. History of significant gastrointestinal bleeding that required intervention within the&#xD;
             prior 1 month is ineligible; inherited bleeding diathesis or coagulopathy.&#xD;
&#xD;
          7. Serious non healing wound and peptic ulcer disease&#xD;
&#xD;
          8. Previous history of intestinal perforation&#xD;
&#xD;
          9. Symptomatic central nervous system (CNS) metastasis&#xD;
&#xD;
         10. Uncontrolled intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, uncontrolled hypertension (systolic &gt;160 mmHg and/or diastolic &gt;100 mmHg),&#xD;
             symptomatic congestive heart failure, unstable angina pectoris, myocardial&#xD;
             infarction/cerebrovascular event (≤ 6 months prior to study entry), cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements, long term systemic immunosuppressant or corticosteroid, and active&#xD;
             viral hepatitis.&#xD;
&#xD;
         11. Women who are breast-feeding or pregnant are excluded from this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei Peng Yong</last_name>
    <role>Principal Investigator</role>
    <affiliation>National University Hospital, Singapore</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Wei Peng Yong</last_name>
    <phone>(65) 6779 5555</phone>
    <email>Wei_Peng_Yong@nuhs.edu.sg</email>
  </overall_contact>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>119074</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wei Peng Yong</last_name>
      <phone>(65) 6779 5555</phone>
      <email>Wei_Peng_Yong@nuhs.edu.sg</email>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <reference>
    <citation>Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol. 2006 Jun 20;24(18):2903-9. Review.</citation>
    <PMID>16782930</PMID>
  </reference>
  <reference>
    <citation>Ishikawa N, Takano A, Yasui W, Inai K, Nishimura H, Ito H, Miyagi Y, Nakayama H, Fujita M, Hosokawa M, Tsuchiya E, Kohno N, Nakamura Y, Daigo Y. Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas. Cancer Res. 2007 Dec 15;67(24):11601-11.</citation>
    <PMID>18089789</PMID>
  </reference>
  <reference>
    <citation>Janunger KG, Hafström L, Nygren P, Glimelius B; SBU-group. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in gastric cancer. Acta Oncol. 2001;40(2-3):309-26. Review.</citation>
    <PMID>11441938</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>December 20, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2018</study_first_posted>
  <last_update_submitted>April 5, 2019</last_update_submitted>
  <last_update_submitted_qc>April 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nivolumab</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>OTSGC-A24</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

